Cargando…

Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy

AIM: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects of the hostile TME, including nutrient deprivation and hypoxia, on immune checkpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Davern, Maria, Donlon, Noel E., O’Connell, Fiona, Gaughan, Caoimhe, O’Donovan, Cillian, McGrath, Jason, Sheppard, Andrew D., Hayes, Conall, King, Ross, Temperley, Hugo, MacLean, Michael, Bulter, Christine, Bhardwaj, Anshul, Moore, Jenny, Donohoe, Claire, Ravi, Narayanasamy, Conroy, Melissa J., Reynolds, John V., Lysaght, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349772/
https://www.ncbi.nlm.nih.gov/pubmed/36445478
http://dx.doi.org/10.1007/s00432-022-04440-0
_version_ 1785073991521665024
author Davern, Maria
Donlon, Noel E.
O’Connell, Fiona
Gaughan, Caoimhe
O’Donovan, Cillian
McGrath, Jason
Sheppard, Andrew D.
Hayes, Conall
King, Ross
Temperley, Hugo
MacLean, Michael
Bulter, Christine
Bhardwaj, Anshul
Moore, Jenny
Donohoe, Claire
Ravi, Narayanasamy
Conroy, Melissa J.
Reynolds, John V.
Lysaght, Joanne
author_facet Davern, Maria
Donlon, Noel E.
O’Connell, Fiona
Gaughan, Caoimhe
O’Donovan, Cillian
McGrath, Jason
Sheppard, Andrew D.
Hayes, Conall
King, Ross
Temperley, Hugo
MacLean, Michael
Bulter, Christine
Bhardwaj, Anshul
Moore, Jenny
Donohoe, Claire
Ravi, Narayanasamy
Conroy, Melissa J.
Reynolds, John V.
Lysaght, Joanne
author_sort Davern, Maria
collection PubMed
description AIM: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects of the hostile TME, including nutrient deprivation and hypoxia, on immune checkpoint (IC) expression and T cell phenotypes, and the potential use of nivolumab to enhance T cell function under such conditions. METHODS AND RESULTS: ICs were upregulated on stromal immune cells within the tumour including PD-L2, CTLA-4 and TIGIT. OAC patient-derived PBMCs co-cultured with OE33 OAC cells upregulated LAG-3 and downregulated the co-stimulatory marker CD27 on T cells, highlighting the direct immunosuppressive effects of tumour cells on T cells. Hypoxia and nutrient deprivation altered the secretome of OAC patient-derived PBMCs, which induced upregulation of PD-L1 and PD-L2 on OE33 OAC cells thus enhancing an immune-resistant phenotype. Importantly, culturing OAC patient-derived PBMCs under dual hypoxia and glucose deprivation, reflective of the conditions within the hostile TME, upregulated an array of ICs on the surface of T cells including PD-1, CTLA-4, A2aR, PD-L1 and PD-L2 and decreased expression of IFN-γ by T cells. Addition of nivolumab under these hostile conditions decreased the production of pro-tumorigenic cytokine IL-10. CONCLUSION: Collectively, these findings highlight the immunosuppressive crosstalk between tumour cells and T cells within the OAC TME. The ability of nivolumab to suppress pro-tumorigenic T cell phenotypes within the hostile TME supports a rationale for the use of immune checkpoint blockade to promote anti-tumour immunity in OAC. GRAPHICAL ABSTRACT: Study schematic: (A) IC expression profiles were assessed on CD45(+) cells in peripheral whole blood and infiltrating tumour tissue from OAC patients in the treatment-naïve setting. (B) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then co-cultured for 48 h with OE33 cells. T cell phenotypes were then assessed by flow cytometry. (C) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then further cultured under conditions of nutrient deprivation or hypoxia for 48 h and T cell phenotypes were then assessed by flow cytometry. Key findings: (A) TIGIT, CTLA-4 and PD-L2 were upregulated on CD45(+) immune cells and CTLA-4 expression on CD45(+) cells correlated with a subsequent decreased response to neoadjuvant regimen. (B) Following a 48 h co-culture with OE33 cells, T cells upregulated LAG-3 and decreased CD27 co-stimulatory marker. (C) Nutrient deprivation and hypoxia upregulated a range of ICs on T cells and decreased IFN-γ production by T cells. Nivolumab decreased IL-10 production by T cells under nutrient deprivation-hypoxic conditions. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04440-0.
format Online
Article
Text
id pubmed-10349772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103497722023-07-17 Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy Davern, Maria Donlon, Noel E. O’Connell, Fiona Gaughan, Caoimhe O’Donovan, Cillian McGrath, Jason Sheppard, Andrew D. Hayes, Conall King, Ross Temperley, Hugo MacLean, Michael Bulter, Christine Bhardwaj, Anshul Moore, Jenny Donohoe, Claire Ravi, Narayanasamy Conroy, Melissa J. Reynolds, John V. Lysaght, Joanne J Cancer Res Clin Oncol Research AIM: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects of the hostile TME, including nutrient deprivation and hypoxia, on immune checkpoint (IC) expression and T cell phenotypes, and the potential use of nivolumab to enhance T cell function under such conditions. METHODS AND RESULTS: ICs were upregulated on stromal immune cells within the tumour including PD-L2, CTLA-4 and TIGIT. OAC patient-derived PBMCs co-cultured with OE33 OAC cells upregulated LAG-3 and downregulated the co-stimulatory marker CD27 on T cells, highlighting the direct immunosuppressive effects of tumour cells on T cells. Hypoxia and nutrient deprivation altered the secretome of OAC patient-derived PBMCs, which induced upregulation of PD-L1 and PD-L2 on OE33 OAC cells thus enhancing an immune-resistant phenotype. Importantly, culturing OAC patient-derived PBMCs under dual hypoxia and glucose deprivation, reflective of the conditions within the hostile TME, upregulated an array of ICs on the surface of T cells including PD-1, CTLA-4, A2aR, PD-L1 and PD-L2 and decreased expression of IFN-γ by T cells. Addition of nivolumab under these hostile conditions decreased the production of pro-tumorigenic cytokine IL-10. CONCLUSION: Collectively, these findings highlight the immunosuppressive crosstalk between tumour cells and T cells within the OAC TME. The ability of nivolumab to suppress pro-tumorigenic T cell phenotypes within the hostile TME supports a rationale for the use of immune checkpoint blockade to promote anti-tumour immunity in OAC. GRAPHICAL ABSTRACT: Study schematic: (A) IC expression profiles were assessed on CD45(+) cells in peripheral whole blood and infiltrating tumour tissue from OAC patients in the treatment-naïve setting. (B) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then co-cultured for 48 h with OE33 cells. T cell phenotypes were then assessed by flow cytometry. (C) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then further cultured under conditions of nutrient deprivation or hypoxia for 48 h and T cell phenotypes were then assessed by flow cytometry. Key findings: (A) TIGIT, CTLA-4 and PD-L2 were upregulated on CD45(+) immune cells and CTLA-4 expression on CD45(+) cells correlated with a subsequent decreased response to neoadjuvant regimen. (B) Following a 48 h co-culture with OE33 cells, T cells upregulated LAG-3 and decreased CD27 co-stimulatory marker. (C) Nutrient deprivation and hypoxia upregulated a range of ICs on T cells and decreased IFN-γ production by T cells. Nivolumab decreased IL-10 production by T cells under nutrient deprivation-hypoxic conditions. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04440-0. Springer Berlin Heidelberg 2022-11-29 2023 /pmc/articles/PMC10349772/ /pubmed/36445478 http://dx.doi.org/10.1007/s00432-022-04440-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Davern, Maria
Donlon, Noel E.
O’Connell, Fiona
Gaughan, Caoimhe
O’Donovan, Cillian
McGrath, Jason
Sheppard, Andrew D.
Hayes, Conall
King, Ross
Temperley, Hugo
MacLean, Michael
Bulter, Christine
Bhardwaj, Anshul
Moore, Jenny
Donohoe, Claire
Ravi, Narayanasamy
Conroy, Melissa J.
Reynolds, John V.
Lysaght, Joanne
Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy
title Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy
title_full Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy
title_fullStr Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy
title_full_unstemmed Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy
title_short Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy
title_sort nutrient deprivation and hypoxia alter t cell immune checkpoint expression: potential impact for immunotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349772/
https://www.ncbi.nlm.nih.gov/pubmed/36445478
http://dx.doi.org/10.1007/s00432-022-04440-0
work_keys_str_mv AT davernmaria nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT donlonnoele nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT oconnellfiona nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT gaughancaoimhe nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT odonovancillian nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT mcgrathjason nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT sheppardandrewd nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT hayesconall nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT kingross nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT temperleyhugo nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT macleanmichael nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT bulterchristine nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT bhardwajanshul nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT moorejenny nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT donohoeclaire nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT ravinarayanasamy nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT conroymelissaj nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT reynoldsjohnv nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy
AT lysaghtjoanne nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy